Phosphate-buffered saline

BIOLOGICAL4 trials

Sponsors

La Jolla Pharmaceutical Company, Vical, United Therapeutics, Institute of Vaccines and Medical Biologicals, Vietnam

Conditions

Bronchopulmonary DysplasiaCOVID-19 DiseaseCOVID-19 VaccineHerpes GenitalisLupus Erythematosus, SystemicLupus NephritisPneumonia, ViralSARS Pneumonia

Phase 1

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

TerminatedNCT03857841

United TherapeuticsBronchopulmonary Dysplasia

Start: 2019-10-09End: 2021-05-20Updated: 2021-10-12

A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)

CompletedNCT04830800

Institute of Vaccines and Medical Biologicals, VietnamCOVID-19 Disease, COVID-19 Vaccine, Pneumonia, Viral +1

Start: 2021-03-10End: 2021-10-31Updated: 2025-02-13

Phase 2

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine

CompletedNCT02837575

VicalHerpes Genitalis

Start: 2016-09-30End: 2018-12-31Updated: 2019-02-27

Phase 3

Study of LJP 394 in Lupus Patients With History of Renal Disease

TerminatedNCT00089804

La Jolla Pharmaceutical CompanyLupus Erythematosus, Systemic, Lupus Nephritis

Start: 2004-10-31End: 2009-02-28Updated: 2009-04-01

Related Papers

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial

Vaccine2024-11-29

Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.

2023-05-1032 citations

Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.

2022-05-1431 citations

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial.

2022-03-0844 citations